GuruTrack
REGN

REGN

REGENERON PHARMACEUTICALS

Data as of 2026 Q2 (06-30) · 13F snapshot

Summary
REGENERON PHARMACEUTICALS (REGN) is held as common stock by 7 tracked hedge-fund managers, with a combined reported value of ~$3.41B; the largest are Dodge & Cox, Izzy Englander, Renaissance Technologies. 4 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 7 added, 1 closed. 20 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Heating up
Common-stock holders74 also report options
Congress trades20
Price$752.25vs quarter-end+20.64%
Sectors1
This quarter's moves
New0
Added7
Trimmed / sold1
Top holderDodge & Cox

Common-stock positions

PUT and CALL disclosures are excluded from these holder counts and values.

PUT / CALL disclosures

Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.

Ken GriffinCALL—
Value $169.17M— of portfolio271,3002026 Q2
Ken GriffinPUT—
Value $164.99M— of portfolio264,6002026 Q2
Izzy EnglanderPUT—
Value $22.51M— of portfolio36,1002026 Q2
Izzy EnglanderCALL—
Value $21.45M— of portfolio34,4002026 Q2
Paul Tudor JonesCALL—
Value $7.98M— of portfolio12,8002026 Q2
Steven CohenCALL—
Value $623.5K— of portfolio1,0002026 Q2
Steven CohenPUT—
Value $623.5K— of portfolio1,0002026 Q2

Insider Trading

Officers · directors · Form 4
Open-market purchases and sales (P/S)17

  • Kathryn Guarini

    Director

    Sell$340.0K
    400 @ $850.00Traded 2026-09-02Filed 2026-09-03

  • Marion Mccourt

    EVP Commercial

    Sell$969.7K
    1,131 @ $857.39Traded 2026-09-02Filed 2026-09-03

  • Marion Mccourt

    EVP Commercial

    Sell$1.03M
    1,215 @ $850.00Traded 2026-09-02Filed 2026-09-03

  • Huda Y Zoghbi

    Director

    Sell$640.0K
    800 @ $800.00Traded 2026-08-10Filed 2026-08-12

  • Kathryn Guarini

    Director

    Sell$320.0K
    400 @ $800.00Traded 2026-08-10Filed 2026-08-12

  • Arthur F Ryan

    Director

    Sell$130.0K
    200 @ $650.15Traded 2026-07-02Filed 2026-07-07

  • Arthur F Ryan

    Director

    Sell$4.3K
    6 @ $709.45Traded 2026-05-01Filed 2026-05-04

  • Arthur F Ryan

    Director

    Sell$16.9K
    24 @ $703.46Traded 2026-05-01Filed 2026-05-04

  • Arthur F Ryan

    Director

    Sell$2.8K
    4 @ $707.40Traded 2026-05-01Filed 2026-05-04

  • Arthur F Ryan

    Director

    Sell$10.5K
    15 @ $702.46Traded 2026-05-01Filed 2026-05-04

  • Arthur F Ryan

    Director

    Sell$3.5K
    5 @ $701.76Traded 2026-05-01Filed 2026-05-04

  • Arthur F Ryan

    Director

    Sell$4.9K
    7 @ $706.74Traded 2026-05-01Filed 2026-05-04

  • Arthur F Ryan

    Director

    Sell$712
    1 @ $712.09Traded 2026-05-01Filed 2026-05-04

  • Arthur F Ryan

    Director

    Sell$9.9K
    14 @ $705.56Traded 2026-05-01Filed 2026-05-04

  • Arthur F Ryan

    Director

    Sell$1.4K
    2 @ $710.87Traded 2026-05-01Filed 2026-05-04

  • Arthur F Ryan

    Director

    Sell$7.0K
    9 @ $777.42Traded 2026-04-01Filed 2026-04-03

  • Arthur F Ryan

    Director

    Sell$10.1K
    13 @ $776.62Traded 2026-04-01Filed 2026-04-03

Insider transactions are public SEC Form 4 disclosures (company officers, directors, 10% owners), for research only — not investment advice.

Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.